Guardian Pharmacy Q3 revenue down 2% to $371.1 million; raises full-year guidance
Guardian Pharmacy Services reported third-quarter 2026 results, with revenue of $371.1 million, down 2% year-over-year and including pricing decreases from the IRA, while net income rose to $19.1 million from $9.6 million. The company raised its full-year 2026 revenue and Adjusted EBITDA guidance, which matters to shareholders because it signals higher expected profitability for the year.
Key points
- Q3 2026 revenue was $371.1 million, down 2% year-over-year; net income was $19.1 million versus $9.6 million a year earlier
- Diluted EPS was $0.29 for the quarter versus $0.15 in the prior-year period; Adjusted EBITDA was $33.9 million, up 24%
- Full-year 2026 guidance raised: revenue to $1.44 billion-$1.46 billion (from $1.43 billion-$1.45 billion) and Adjusted EBITDA to $136 million-$138 million (from $129 million-$131 million)
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.